medcelerator · clinician one-pager
Weekly Treatment for Children with Achondroplasia
Yuviwel (navepegritide) — once-weekly CNP analog for children ≥2 with achondroplasia
FDA Approved · United States · September 11, 2026
Condition: Achondroplasia
Who this is for
This is for families of children aged 2 years and older with achondroplasia and open growth plates who may be candidates for a labelled US once-weekly subcutaneous CNP-analog injection. It explains the FDA accelerated label, the ApproaCH AGV numbers behind approval, blood-pressure and injection-site watchpoints, reconstitution / weekly injection logistics, the confirmatory final-adult-height requirement, and how to talk with a pediatric endocrinology or skeletal dysplasia clinician — without treating a Montreal trial site, an EMA MAA under review, or a DIY import as the care plan. Confirmatory final adult height work is still required; authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf
United States · Recruiting clinical trial
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
Combination or different setting. Infants under 2; the label is age 2+ (phase 2).
https://clinicaltrials.gov/study/NCT06079398
See 1 trial on ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=achondroplasia&intr=navepegritide&aggFilters=status:rec
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/yuviwel-navepegritide